Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. [electronic resource]
Producer: 20011011Description: 839-45 p. digitalISSN:- 0041-1337
- Acute Disease
- Adrenal Cortex Hormones -- administration & dosage
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Humanized
- Azathioprine -- administration & dosage
- Cyclosporine -- administration & dosage
- Daclizumab
- Graft Rejection -- prevention & control
- Graft Survival
- Humans
- Immunoglobulin G -- adverse effects
- Immunosuppressive Agents -- adverse effects
- Kidney Transplantation -- adverse effects
- Lymphoproliferative Disorders -- etiology
- Neoplasms -- etiology
- Receptors, Interleukin-2 -- antagonists & inhibitors
- Survival Rate
- Time Factors
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.